GT Biopharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1965-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.gtbiopharma.com
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
- Conditions
- Mast Cell LeukemiaAcute Myelogenous LeukemiaHigh-risk Myelodysplastic SyndromesSystemic Mastocytosis
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- GT Biopharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03214666
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
News
GT Biopharma Advances GTB-3650 Phase 1 Trial to Second Cohort Following Promising Immune Activation Signals
GT Biopharma has successfully completed dosing in the first cohort of its Phase 1 trial for GTB-3650, a second-generation TriKE immunotherapy, with no safety or tolerability issues observed.
GT Biopharma Secures $0.7M Through Strategic Warrant Exercise for TriKE® Platform Development
GT Biopharma has secured approximately $0.7 million in gross proceeds through the exercise of existing warrants at $4.35 per share, strengthening its financial position for TriKE® platform development.
GT Biopharma Doses First Patient in Phase 1 Trial of GTB-3650 for Hematologic Malignancies
GT Biopharma initiated a Phase 1 trial of GTB-3650, a second-generation TriKE, for relapsed or refractory CD33-expressing hematologic malignancies.